Needham & Company maintains a 'Strong Buy' on Mylan (MYL); PRX Grossly Undervalued by TGP, MYL/PRX Instead As Strong Combo

Article Stock Quotes (4) Comments (0)

Needham & Company maintains a 'Strong Buy' on Mylan (NASDAQ: MYL) price target of $30.00.

Analyst, Elliot Wilbur, said, "Mylan competitor Par Pharmaceutical (PRX) is in play following a $50 bid from private equity shop TPG. We believe TPG’s $50/share ($1.9B) offer, a multiple of 7.5X 2012E EBITDA, grossly undervalues PRX considering substantial synergies that could be realized by a strategic acquirer. We think value optimization would be most realizable by a strategic buyer that could effectively take PRX’s key revenue-generating assets and its pipeline and leave the rest. Few players besides Teva, Watson, Sandoz and Mylan seem to have the capability to acquire Par (NYSE: PRX), and with Watson (NYSE: WPI) busy closing the Actavis deal and Teva (Nasdaq: TEVA) reformulating strategy under new management, MYL appears best positioned to act."

For an analyst ratings summary and ratings history on Mylan click here. For more ratings news on Mylan click here.

Shares of Mylan closed at $22.61 yesterday, with a 52 week range of $15.49-$23.94.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
• Supernus (SUPN) PT Trimmed at Jefferies, But Survey Shows Significant Market Opportunity
• UPDATE: Macquarie Downgrades Barrick Gold (ABX) to Underperform

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Mergers and Acquisitions

Related Entities

Needham & Company

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?